Evidence map›Paper›PMID 38123705›Full record

ArticleBritish journal of cancer2024

Stroma AReactive Invasion Front Areas (SARIFA) improves prognostic risk stratification of perioperative chemotherapy treated oesophagogastric cancer patients from the MAGIC and the ST03 trial.

Bianca Grosser, Jake Emmerson, Nic G Reitsam, David Cunningham, Matthew Nankivell, Ruth E Langley, William H Allum, Martin Trepel, Bruno Märkl, Heike I Grabsch

Open access · hybridAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in British journal of cancer, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 13 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
13citing papers in PubMed, 1 pooled it
2.9field-weighted citation impact, top 9% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

13 citing papers in PubMed, 1 synthesis or guideline pooled it, 12 citations in OpenAlex.

  1. Pooled it
  2. Review
  3. Review
  4. Review
  5. Review
  6. Article
  7. Article
  8. Article
  9. Article
  10. [SARIFA-a new multi-entity biomarker].Pathologie (Heidelberg, Germany) · 2024
    Review
  11. Article
  12. Article
  13. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors at 4 institutions in 3 countries.

Bianca GrosserPathology, Medical Faculty Augsburg, University of Augsburg, Augsburg, Germany.
Jake EmmersonLeeds Institute of Clinical Trials Research, University of Leeds, Leeds, UK.ORCID 0000-0002-8198-8043
Nic G ReitsamPathology, Medical Faculty Augsburg, University of Augsburg, Augsburg, Germany.ORCID 0000-0002-0070-3158
David CunninghamDepartment of Medicine, Royal Marsden Hospital, Sutton, Surrey, UK.ORCID 0000-0001-5158-1069
Matthew NankivellMedical Research Council Clinical Trials Unit at University College London, London, UK.
Ruth E LangleyMedical Research Council Clinical Trials Unit at University College London, London, UK.ORCID 0000-0002-9706-016X
William H AllumDepartment of Oncology and Department of Surgery, Royal Marsden NHS Foundation Trust, London, UK.
Martin TrepelHaematology and Oncology, Medical Faculty Augsburg, University of Augsburg, Augsburg, Germany.
Bruno MärklPathology, Medical Faculty Augsburg, University of Augsburg, Augsburg, Germany. bruno.maerkl@uka-science.de.
Heike I GrabschDepartment of Pathology, GROW School for Oncology and Reproduction, Maastricht University Medical Center+, Maastricht, The Netherlands. h.grabsch@maastrichtuniversity.nl.ORCID 0000-0001-9520-6228
University of Augsburg · DERoyal Marsden NHS Foundation Trust · GBUniversity College London · GBUniversity of Leeds · GB

Funding

Medical Research Council MC_UU_12023/20
6 · The paper itself

Abstract

backgroundTumour-associated fat cells without desmoplastic stroma reaction at the invasion front (Stroma AReactive Invasion Front Areas (SARIFA)) is a prognostic biomarker in gastric and colon cancer. The clinical utility of the SARIFA status in oesophagogastric cancer patients treated with perioperative chemotherapy is currently unknown.

methodsThe SARIFA status was determined in tissue sections from patients recruited into the MAGIC (n = 292) or ST03 (n = 693) trials treated with surgery alone (S, MAGIC) or perioperative chemotherapy (MAGIC, ST03). The relationship between SARIFA status, clinicopathological factors, overall survival (OS) and treatment was analysed.

resultsThe SARIFA status was positive in 42% MAGIC trial S patients, 28% MAGIC and 48% ST03 patients after pre-operative chemotherapy. SARIFA status was related to OS in MAGIC trial S patients and was an independent prognostic biomarker in ST03 trial patients (HR 1.974, 95% CI 1.555-2.507, p < 0.001). ST03 patients with lymph node metastasis (ypN + ) and SARIFA-positive tumours had poorer OS than patients with ypN+ and SARIFA-negative tumours (p

conclusionsThe SARIFA status has clinical utility as prognostic biomarker in oesophagogastric cancer patients irrespective of treatment modality. Whilst underlying biological mechanisms warrant further investigation, the SARIFA status might be used to identify new drug targets, potentially enabling repurposing of existing drugs targeting lipid metabolism.

Indexed as

AdenocarcinomaStomach NeoplasmsAntineoplastic Combined Chemotherapy ProtocolsBiomarkersHumansPrognosisRisk AssessmentBiomarkers

Identifiers

PMID38123705
PMCPMC10844337
OpenAlexW4389993425

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.